ADIM
CFLT

Alpha DNA Investment Management’s Confluent CFLT Stock Holding History

Alpha DNA Investment Management’s Portfolio CFLT Stock Details CFLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,435
Closed -$1.12M – 158
2022
Q4 		$1.12M Buy
+50,435
New +$1.17M 0.4% 66
2022
Q1 		– Sell
-20,299
Closed -$1.55M – 125
2021
Q4 		$1.55M Buy
+20,299
New +$1.46M 0.98% 57

Other funds holding CFLT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
AM
Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Alpha DNA Investment Management's CFLT Position: Q1 2023 in Review

Alpha DNA Investment Management sold out of Confluent (CFLT) in Q1 2023, closing a stake of 50,435 shares — an estimated $1.12M sold.

Alpha DNA Investment Management first reported a position in CFLT in Q4 2021 and held it in 2 quarters. The position peaked at $1.55M in Q4 2021. 259 funds tracked by Wall St. Rank hold CFLT as of Q1 2023.

  • Alpha DNA Investment Management reported no remaining Confluent position as of Q1 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 50,435 Confluent shares in Q1 2023, an estimated $1.12M.
  • Alpha DNA Investment Management first reported a position in Confluent in Q4 2021 and held it in 2 quarters.
  • Alpha DNA Investment Management's Confluent position peaked at $1.55M in Q4 2021.
  • 259 funds tracked by Wall St. Rank held Confluent as of Q1 2023.

Based on Alpha DNA Investment Management's 13F filing for Q1 2023, filed 5 May 2023.